Shots: Agios to receive ~$1.8B upfront in cash & ~$200M as regulatory milestones for Vorasidenib along with 5% royalties on sales of Tibsovo in the US from transaction close through […]readmore
Tags : $2B
Shots: Takeda to receive $120M as upfront in cash, ~ $495M as development milestones, and ~$1.4B as commercial milestones along with royalties on net sales of the therapies. Takeda retains […]readmore